SCHEMBL6023909

SCHEMBL6023909

COc1ccc(/C=C/C(=O)O)cc1-c1ccc(OCc2ccccc2)c(C23CC4CC(CC(C4)C2)C3)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC11 Q96DB2 4/20 0.57
HDAC2 Q92769 1/20 0.54
PTPN11 Q06124 4/20 0.51
NR0B2 Q15466 2/20 0.51
LMNA P02545 2/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
KDM4E B2RXH2 1/20 0.50
RARB P10826 1/20 0.49
ALDH1A1 P00352 1/20 0.48
TP53 P04637 1/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
APP P05067 7/20 0.48
PTGER4 P35408 1/20 0.47
PTGER3 P43115 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6023917 1.00 HDAC11 (0.57) HDAC11HDAC2PTPN11NR0B2LMNA
SCHEMBL2392187 0.91 HDAC11 (0.50) HDAC11HDAC2LMNAHDAC1HDAC7
SCHEMBL2391031 0.90 HDAC11 (0.56) HDAC11HDAC2PTPN11NR0B2LMNA
SCHEMBL6022855 0.90 PTPN11 (0.58) HDAC11HDAC2PTPN11NR0B2LMNA
SCHEMBL6022849 0.90 PTPN11 (0.58) HDAC11HDAC2PTPN11NR0B2LMNA
SCHEMBL6022648 0.90 HDAC11 (0.57) HDAC11HDAC2PTPN11NR0B2LMNA
SCHEMBL6022887 0.90 PTPN11 (0.59) HDAC11HDAC2PTPN11NR0B2LMNA
SCHEMBL6022883 0.90 PTPN11 (0.59) HDAC11HDAC2PTPN11NR0B2LMNA
SCHEMBL6022644 0.90 HDAC11 (0.57) HDAC11HDAC2PTPN11NR0B2LMNA
SCHEMBL6022534 0.89 HDAC11 (0.56) HDAC11HDAC2LMNAHDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053071-B2 For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells THE BURNHAM INSTITUTE (US) 2006-05-30 US disclosed
EP-1456165-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS The Burnham Institute (US) 2004-09-15 EP disclosed
US-20030176506-A1 Induction of apoptosis in cancer cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH 2003-09-18 US disclosed
WO-2003048101-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS THE BURNHAM INSTITUTE (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176506-A1 Induction of apoptosis in cancer cells MCL1, BAD, BCL2 HDAC11 347/4885HDAC2 792/4885PTPN11 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.